Syra Health (SYRA) reported second-quarter 2026 revenue of $2.4 million, up 23% from the prior-year period, and net income of $250,242 compared with a net loss of $63,596 a year earlier.
The company said gross margin rose to 44.5% from 38.7% in Q2 2025. Syra Health also reported EPS of $0.02, compared with a loss of $0.01 per share in the prior-year quarter.
- Second-quarter revenue was $2.4 million, up 23% year over year.
- Net income was $250,242, compared with a net loss of $63,596 in Q2 2025.
- Basic and diluted net income per share was $0.02.
- Gross margin increased to 44.5%, up from 38.7% a year earlier.
- For the first six months of 2026, net income was $491,221, compared with a net loss of $535,861 in the prior-year period.
- Net cash provided by operating activities for the six months ended June 30, 2026, was $643,183.
- Cash and cash equivalents were $2.1 million as of June 30, 2026, with no long-term debt.
